Overview

Diabetes Islet Preservation Immune Treatment

Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
To assess whether there is a difference in endogenous insulin secretion, measured as stimulated C-peptide secretion (area under the curve during a 4-hour mixed meal tolerance test), at the 1 year visit, for study subjects receiving combinational therapy versus those receiving placebo. The study will also examine the effect of the proposed treatments on immunological outcomes, specifically proportion of regulatory T cells at the 1 year visit.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Camillo Ricordi and Jay Skyler
Collaborator:
Diabetes Research Institute Foundation
Treatments:
Adalimumab
Aldesleukin
Antilymphocyte Serum
Etanercept
Exenatide
Interleukin-2
Lenograstim
Thymoglobulin